 Uwe Christians
Concepts (1132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 848 | 11.910 |
Why?
| | Sirolimus | 60 | 2025 | 277 | 6.830 |
Why?
| | Cyclosporine | 74 | 2019 | 266 | 6.390 |
Why?
| | Tandem Mass Spectrometry | 38 | 2025 | 556 | 5.280 |
Why?
| | Tacrolimus | 46 | 2019 | 191 | 4.330 |
Why?
| | Chromatography, High Pressure Liquid | 68 | 2024 | 590 | 4.260 |
Why?
| | Drug Monitoring | 23 | 2020 | 209 | 3.640 |
Why?
| | Kidney Transplantation | 46 | 2018 | 658 | 3.140 |
Why?
| | Chromatography, Liquid | 26 | 2024 | 449 | 2.510 |
Why?
| | Mycophenolic Acid | 15 | 2017 | 117 | 2.340 |
Why?
| | Metabolomics | 18 | 2022 | 689 | 2.250 |
Why?
| | Kidney | 25 | 2022 | 1467 | 2.190 |
Why?
| | Microsomes, Liver | 19 | 2019 | 81 | 2.060 |
Why?
| | Everolimus | 25 | 2020 | 109 | 1.990 |
Why?
| | Mass Spectrometry | 34 | 2021 | 739 | 1.810 |
Why?
| | Biomarkers | 28 | 2025 | 4095 | 1.680 |
Why?
| | Dronabinol | 16 | 2025 | 238 | 1.590 |
Why?
| | Graft Rejection | 26 | 2019 | 534 | 1.420 |
Why?
| | Liver Transplantation | 28 | 2018 | 754 | 1.370 |
Why?
| | Proteomics | 18 | 2024 | 1112 | 1.270 |
Why?
| | Cannabinoids | 9 | 2025 | 168 | 1.210 |
Why?
| | Cannabidiol | 7 | 2025 | 123 | 1.190 |
Why?
| | Plant Extracts | 6 | 2024 | 209 | 1.110 |
Why?
| | Cannabis | 12 | 2024 | 500 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.050 |
Why?
| | Oxidative Stress | 17 | 2019 | 1318 | 1.040 |
Why?
| | Cytochrome P-450 CYP3A | 20 | 2021 | 89 | 1.030 |
Why?
| | Organ Transplantation | 10 | 2019 | 242 | 1.010 |
Why?
| | Rats | 62 | 2024 | 5591 | 1.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2017 | 442 | 1.000 |
Why?
| | Humans | 240 | 2025 | 138972 | 0.990 |
Why?
| | Hallucinogens | 6 | 2024 | 110 | 0.990 |
Why?
| | Pravastatin | 9 | 2021 | 41 | 0.970 |
Why?
| | Dried Blood Spot Testing | 3 | 2020 | 121 | 0.960 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 182 | 0.930 |
Why?
| | Hydrocortisone | 3 | 2025 | 313 | 0.930 |
Why?
| | Drug Interactions | 27 | 2025 | 404 | 0.930 |
Why?
| | Reproducibility of Results | 27 | 2025 | 3313 | 0.910 |
Why?
| | Immunoassay | 3 | 2020 | 111 | 0.900 |
Why?
| | Cytochrome P-450 Enzyme System | 17 | 2019 | 158 | 0.900 |
Why?
| | Metabolome | 5 | 2022 | 352 | 0.860 |
Why?
| | Animals | 120 | 2025 | 37243 | 0.830 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 260 | 0.810 |
Why?
| | Proteome | 5 | 2017 | 471 | 0.810 |
Why?
| | Mitochondria | 6 | 2017 | 958 | 0.810 |
Why?
| | Factor Xa Inhibitors | 2 | 2025 | 170 | 0.800 |
Why?
| | Lovastatin | 7 | 2013 | 38 | 0.780 |
Why?
| | Drugs, Generic | 4 | 2019 | 25 | 0.780 |
Why?
| | Intestinal Mucosa | 7 | 2017 | 620 | 0.760 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 448 | 0.750 |
Why?
| | Male | 140 | 2025 | 68250 | 0.750 |
Why?
| | Nucleotides | 2 | 2017 | 128 | 0.740 |
Why?
| | Isoprostanes | 4 | 2012 | 15 | 0.730 |
Why?
| | Pharmaceutical Preparations | 3 | 2017 | 176 | 0.720 |
Why?
| | Magnetic Resonance Spectroscopy | 18 | 2017 | 611 | 0.720 |
Why?
| | Biological Availability | 12 | 2019 | 137 | 0.720 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 205 | 0.720 |
Why?
| | Cortisone | 1 | 2021 | 15 | 0.720 |
Why?
| | Female | 116 | 2025 | 74016 | 0.690 |
Why?
| | Pregnanolone | 1 | 2021 | 40 | 0.690 |
Why?
| | TOR Serine-Threonine Kinases | 7 | 2016 | 416 | 0.690 |
Why?
| | Cyclosporins | 18 | 2001 | 71 | 0.680 |
Why?
| | Endocannabinoids | 5 | 2025 | 64 | 0.680 |
Why?
| | Transplant Recipients | 4 | 2019 | 174 | 0.670 |
Why?
| | Urine | 2 | 2017 | 62 | 0.670 |
Why?
| | Drug-Eluting Stents | 7 | 2025 | 84 | 0.660 |
Why?
| | Estrogen Receptor beta | 2 | 2012 | 42 | 0.660 |
Why?
| | Energy Metabolism | 17 | 2022 | 927 | 0.650 |
Why?
| | Dinoprost | 6 | 2019 | 46 | 0.640 |
Why?
| | Hemorrhage | 2 | 2025 | 747 | 0.630 |
Why?
| | Progesterone | 1 | 2021 | 258 | 0.630 |
Why?
| | Dose-Response Relationship, Drug | 25 | 2024 | 2047 | 0.620 |
Why?
| | Therapeutic Equivalency | 6 | 2019 | 31 | 0.620 |
Why?
| | Limit of Detection | 11 | 2024 | 91 | 0.610 |
Why?
| | Pharmacology | 1 | 2019 | 12 | 0.610 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 47 | 0.600 |
Why?
| | Tissue Distribution | 12 | 2019 | 330 | 0.600 |
Why?
| | Signal Transduction | 11 | 2017 | 5092 | 0.580 |
Why?
| | Models, Biological | 9 | 2021 | 1810 | 0.570 |
Why?
| | Brain | 13 | 2019 | 2791 | 0.570 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.550 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 32 | 0.540 |
Why?
| | Intestine, Small | 5 | 2006 | 156 | 0.530 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 30 | 0.530 |
Why?
| | Toxicity Tests | 1 | 2017 | 40 | 0.530 |
Why?
| | Menopause | 3 | 2019 | 326 | 0.530 |
Why?
| | Cardiovascular Agents | 5 | 2025 | 156 | 0.530 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2024 | 611 | 0.530 |
Why?
| | Rats, Wistar | 16 | 2024 | 453 | 0.530 |
Why?
| | Anticoagulants | 2 | 2020 | 667 | 0.500 |
Why?
| | Myocardium | 4 | 2017 | 921 | 0.500 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.490 |
Why?
| | Helminth Proteins | 1 | 2016 | 25 | 0.490 |
Why?
| | Choline | 3 | 2022 | 131 | 0.480 |
Why?
| | Lipid Metabolism | 2 | 2017 | 523 | 0.470 |
Why?
| | Marijuana Smoking | 4 | 2025 | 261 | 0.470 |
Why?
| | Kidney Diseases | 3 | 2018 | 403 | 0.470 |
Why?
| | Fishes | 1 | 2016 | 111 | 0.460 |
Why?
| | Substance Abuse Detection | 4 | 2025 | 101 | 0.450 |
Why?
| | Clinical Laboratory Techniques | 1 | 2015 | 95 | 0.450 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 322 | 0.450 |
Why?
| | Oxidoreductases, N-Demethylating | 6 | 2004 | 16 | 0.450 |
Why?
| | Analgesics, Opioid | 8 | 2021 | 1092 | 0.450 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 203 | 0.440 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1939 | 0.430 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.430 |
Why?
| | Amino Acids | 3 | 2016 | 497 | 0.430 |
Why?
| | Premature Birth | 3 | 2025 | 343 | 0.430 |
Why?
| | Adult | 62 | 2025 | 38393 | 0.420 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 168 | 0.420 |
Why?
| | Polyenes | 8 | 1998 | 16 | 0.420 |
Why?
| | Hydroxyurea | 1 | 2013 | 36 | 0.410 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 40 | 0.410 |
Why?
| | Molecular Structure | 10 | 2014 | 498 | 0.410 |
Why?
| | Metabolic Clearance Rate | 9 | 2019 | 116 | 0.410 |
Why?
| | Protein Kinases | 4 | 2017 | 308 | 0.400 |
Why?
| | Anticholesteremic Agents | 4 | 2007 | 151 | 0.400 |
Why?
| | Piperazines | 4 | 2009 | 345 | 0.400 |
Why?
| | Coated Materials, Biocompatible | 3 | 2020 | 65 | 0.390 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 91 | 0.390 |
Why?
| | Pyrimidines | 4 | 2014 | 472 | 0.380 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.380 |
Why?
| | Drug Therapy, Combination | 18 | 2025 | 1031 | 0.380 |
Why?
| | Liver | 14 | 2023 | 1807 | 0.380 |
Why?
| | Middle Aged | 49 | 2025 | 33782 | 0.380 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 850 | 0.380 |
Why?
| | Administration, Oral | 12 | 2025 | 787 | 0.380 |
Why?
| | Heart Transplantation | 8 | 2017 | 707 | 0.380 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2012 | 32 | 0.370 |
Why?
| | In Vitro Techniques | 18 | 2017 | 1090 | 0.370 |
Why?
| | Vasomotor System | 1 | 2012 | 47 | 0.370 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2152 | 0.360 |
Why?
| | Hypoxia | 6 | 2024 | 1148 | 0.360 |
Why?
| | Macrophages, Alveolar | 4 | 2016 | 396 | 0.360 |
Why?
| | Lung Transplantation | 8 | 2000 | 313 | 0.340 |
Why?
| | Area Under Curve | 9 | 2021 | 319 | 0.340 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2021 | 26 | 0.340 |
Why?
| | Swine | 15 | 2017 | 800 | 0.340 |
Why?
| | Microsomes | 5 | 1998 | 33 | 0.340 |
Why?
| | Artifacts | 1 | 2011 | 130 | 0.340 |
Why?
| | Young Adult | 25 | 2025 | 13371 | 0.340 |
Why?
| | Acetaminophen | 1 | 2013 | 261 | 0.330 |
Why?
| | Hydroxylation | 5 | 2019 | 45 | 0.320 |
Why?
| | Prospective Studies | 18 | 2025 | 7661 | 0.320 |
Why?
| | Graft Survival | 6 | 2018 | 490 | 0.320 |
Why?
| | Double-Blind Method | 11 | 2025 | 1949 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 18 | 2023 | 2497 | 0.320 |
Why?
| | Calcineurin Inhibitors | 6 | 2014 | 70 | 0.310 |
Why?
| | Phosphates | 5 | 2012 | 180 | 0.310 |
Why?
| | Drug Approval | 1 | 2010 | 91 | 0.310 |
Why?
| | Isoniazid | 2 | 2006 | 61 | 0.310 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4316 | 0.300 |
Why?
| | Cell Proliferation | 10 | 2020 | 2480 | 0.300 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 935 | 0.300 |
Why?
| | Bile | 7 | 1992 | 25 | 0.300 |
Why?
| | Lidocaine | 2 | 2023 | 53 | 0.300 |
Why?
| | Theophylline | 2 | 2020 | 42 | 0.300 |
Why?
| | Time Factors | 19 | 2025 | 6869 | 0.300 |
Why?
| | Diltiazem | 3 | 1997 | 19 | 0.300 |
Why?
| | Pain, Postoperative | 3 | 2018 | 309 | 0.290 |
Why?
| | Glucose | 7 | 2017 | 1031 | 0.290 |
Why?
| | Flavanones | 1 | 2008 | 7 | 0.290 |
Why?
| | Cross-Over Studies | 6 | 2025 | 555 | 0.290 |
Why?
| | Drugs, Chinese Herbal | 1 | 2008 | 21 | 0.290 |
Why?
| | Paclitaxel | 3 | 2020 | 237 | 0.290 |
Why?
| | Pregnancy | 13 | 2025 | 6870 | 0.290 |
Why?
| | Adolescent | 30 | 2025 | 21581 | 0.290 |
Why?
| | Medical Marijuana | 2 | 2021 | 123 | 0.290 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 68 | 0.290 |
Why?
| | Child | 25 | 2022 | 21936 | 0.280 |
Why?
| | Neurons | 3 | 2019 | 1602 | 0.280 |
Why?
| | Liver Function Tests | 5 | 2025 | 105 | 0.280 |
Why?
| | Biotransformation | 18 | 2021 | 62 | 0.270 |
Why?
| | Buprenorphine | 2 | 2021 | 174 | 0.270 |
Why?
| | Calcium Channel Blockers | 3 | 1997 | 172 | 0.270 |
Why?
| | Naltrexone | 1 | 2008 | 102 | 0.270 |
Why?
| | Angioplasty, Balloon | 3 | 2020 | 93 | 0.260 |
Why?
| | Drug Stability | 4 | 2013 | 164 | 0.260 |
Why?
| | Lipase | 2 | 2020 | 67 | 0.260 |
Why?
| | Pyridostigmine Bromide | 1 | 2006 | 5 | 0.260 |
Why?
| | Half-Life | 8 | 2019 | 146 | 0.260 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 38 | 0.250 |
Why?
| | Tachycardia | 1 | 2006 | 55 | 0.250 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 45 | 0.250 |
Why?
| | Coronary Artery Disease | 3 | 2025 | 695 | 0.250 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 1811 | 0.250 |
Why?
| | Glomerular Filtration Rate | 8 | 2022 | 741 | 0.250 |
Why?
| | Reactive Oxygen Species | 4 | 2010 | 627 | 0.250 |
Why?
| | Macaca fascicularis | 13 | 2008 | 68 | 0.250 |
Why?
| | Drug Carriers | 2 | 2020 | 126 | 0.240 |
Why?
| | Fibrinolytic Agents | 2 | 2025 | 280 | 0.240 |
Why?
| | Regression Analysis | 5 | 2020 | 1021 | 0.240 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 48 | 0.240 |
Why?
| | Mice | 19 | 2025 | 17828 | 0.240 |
Why?
| | Dogs | 6 | 2025 | 425 | 0.240 |
Why?
| | Drug Delivery Systems | 4 | 2020 | 359 | 0.240 |
Why?
| | Mice, Knockout | 6 | 2019 | 3029 | 0.240 |
Why?
| | Pipecolic Acids | 1 | 2025 | 26 | 0.240 |
Why?
| | Coronary Thrombosis | 1 | 2025 | 24 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 335 | 0.240 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3397 | 0.240 |
Why?
| | Depression | 3 | 2025 | 1470 | 0.230 |
Why?
| | Isomerism | 2 | 2024 | 55 | 0.230 |
Why?
| | Heptanoic Acids | 2 | 2007 | 66 | 0.230 |
Why?
| | Corticosterone | 2 | 2024 | 242 | 0.230 |
Why?
| | Caffeine | 1 | 2025 | 66 | 0.230 |
Why?
| | Wound Infection | 1 | 2025 | 35 | 0.230 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 71 | 0.230 |
Why?
| | Drug Synergism | 7 | 2014 | 367 | 0.230 |
Why?
| | Catheters | 2 | 2017 | 73 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Cholic Acid | 1 | 2024 | 4 | 0.230 |
Why?
| | Oxylipins | 1 | 2025 | 41 | 0.230 |
Why?
| | Inflammation | 9 | 2025 | 2853 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 7 | 0.220 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 397 | 0.220 |
Why?
| | Infant, Newborn | 12 | 2024 | 6158 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 32 | 0.220 |
Why?
| | Ketorolac | 2 | 2017 | 25 | 0.220 |
Why?
| | Clemastine | 1 | 2024 | 1 | 0.220 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 850 | 0.220 |
Why?
| | Benzylidene Compounds | 2 | 2017 | 20 | 0.220 |
Why?
| | Diphosphonates | 1 | 2025 | 69 | 0.220 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.220 |
Why?
| | Animals, Newborn | 3 | 2024 | 859 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 121 | 0.220 |
Why?
| | Pyrroles | 2 | 2007 | 210 | 0.220 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 85 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 28 | 0.210 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1746 | 0.210 |
Why?
| | Cholesterol | 5 | 2013 | 403 | 0.210 |
Why?
| | Mice, Inbred C57BL | 10 | 2024 | 5801 | 0.210 |
Why?
| | Protease Inhibitors | 1 | 2004 | 104 | 0.210 |
Why?
| | Kinetics | 8 | 2013 | 1649 | 0.210 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 22 | 0.210 |
Why?
| | Gestational Age | 3 | 2022 | 918 | 0.210 |
Why?
| | Cell Line | 7 | 2017 | 2879 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 515 | 0.210 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 176 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 239 | 0.210 |
Why?
| | Niacinamide | 1 | 2024 | 82 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 63 | 0.210 |
Why?
| | Morphine | 2 | 2018 | 171 | 0.210 |
Why?
| | Deoxycytidine | 1 | 2025 | 192 | 0.210 |
Why?
| | Leukemia | 2 | 2020 | 241 | 0.200 |
Why?
| | Anti-HIV Agents | 3 | 2013 | 836 | 0.200 |
Why?
| | Child, Preschool | 12 | 2024 | 11158 | 0.200 |
Why?
| | Macrolides | 1 | 2003 | 67 | 0.200 |
Why?
| | Rivaroxaban | 1 | 2025 | 256 | 0.200 |
Why?
| | Mixed Function Oxygenases | 5 | 2001 | 48 | 0.200 |
Why?
| | Adiponectin | 1 | 2025 | 240 | 0.200 |
Why?
| | Transplantation | 4 | 2016 | 33 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.200 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 546 | 0.200 |
Why?
| | Neurofibromatosis 1 | 2 | 2015 | 56 | 0.190 |
Why?
| | Glycolysis | 4 | 2012 | 320 | 0.190 |
Why?
| | Psychomotor Performance | 1 | 2025 | 317 | 0.190 |
Why?
| | Hepatitis C | 1 | 2005 | 247 | 0.190 |
Why?
| | Blotting, Western | 8 | 2012 | 1232 | 0.190 |
Why?
| | Rats, Inbred Lew | 11 | 2012 | 113 | 0.190 |
Why?
| | Blood Transfusion | 1 | 2025 | 377 | 0.190 |
Why?
| | White Matter | 1 | 2024 | 144 | 0.190 |
Why?
| | Glutamine | 3 | 2012 | 104 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 558 | 0.190 |
Why?
| | Pharmacogenetics | 3 | 2010 | 164 | 0.190 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 92 | 0.190 |
Why?
| | Kidney Failure, Chronic | 4 | 2017 | 575 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.180 |
Why?
| | Heart Rate, Fetal | 1 | 2021 | 24 | 0.180 |
Why?
| | Homocysteine | 2 | 2019 | 154 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 496 | 0.180 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 81 | 0.180 |
Why?
| | Prostaglandins | 2 | 2019 | 101 | 0.180 |
Why?
| | Kynurenine | 2 | 2022 | 115 | 0.180 |
Why?
| | Biological Transport, Active | 5 | 2006 | 71 | 0.180 |
Why?
| | Hepatectomy | 2 | 2023 | 240 | 0.180 |
Why?
| | Transplantation, Heterologous | 3 | 2006 | 193 | 0.180 |
Why?
| | Arginine | 2 | 2025 | 261 | 0.170 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2020 | 39 | 0.170 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 184 | 0.170 |
Why?
| | Pilot Projects | 8 | 2023 | 1765 | 0.170 |
Why?
| | Fetal Development | 2 | 2021 | 298 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2018 | 406 | 0.170 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 125 | 0.170 |
Why?
| | Pain | 2 | 2025 | 779 | 0.170 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 112 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 153 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2018 | 196 | 0.170 |
Why?
| | Anesthetics, Intravenous | 2 | 2016 | 63 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2023 | 226 | 0.170 |
Why?
| | Pyridines | 2 | 2017 | 494 | 0.170 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 11 | 0.170 |
Why?
| | Microspheres | 2 | 2020 | 135 | 0.170 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 850 | 0.170 |
Why?
| | Avoidance Learning | 2 | 2024 | 74 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 325 | 0.170 |
Why?
| | Coronary Restenosis | 2 | 2010 | 21 | 0.160 |
Why?
| | Infant | 11 | 2024 | 9577 | 0.160 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 411 | 0.160 |
Why?
| | Keratosis | 1 | 2020 | 16 | 0.160 |
Why?
| | Glutamic Acid | 2 | 2018 | 255 | 0.160 |
Why?
| | Treatment Outcome | 12 | 2025 | 10921 | 0.160 |
Why?
| | Aged | 18 | 2025 | 24172 | 0.160 |
Why?
| | Lactones | 1 | 2000 | 58 | 0.160 |
Why?
| | Losartan | 1 | 2000 | 14 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 403 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 488 | 0.160 |
Why?
| | Tetrazoles | 1 | 2000 | 43 | 0.160 |
Why?
| | Amygdala | 3 | 2024 | 191 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 53 | 0.160 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 126 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 153 | 0.160 |
Why?
| | Carotid Arteries | 2 | 2018 | 195 | 0.160 |
Why?
| | Reference Standards | 5 | 2016 | 184 | 0.160 |
Why?
| | Adenosine | 4 | 2017 | 241 | 0.160 |
Why?
| | Mental Disorders | 2 | 2021 | 1095 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 68 | 0.160 |
Why?
| | Opiate Substitution Treatment | 1 | 2021 | 156 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 118 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 98 | 0.160 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 111 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 90 | 0.150 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2283 | 0.150 |
Why?
| | Age Factors | 7 | 2018 | 3276 | 0.150 |
Why?
| | Astrocytes | 4 | 2011 | 217 | 0.150 |
Why?
| | Case-Control Studies | 7 | 2025 | 3574 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
| | Postoperative Complications | 5 | 2018 | 2716 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 86 | 0.150 |
Why?
| | Perfusion | 6 | 2017 | 225 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 36 | 0.150 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 98 | 0.150 |
Why?
| | Spine | 1 | 2021 | 179 | 0.150 |
Why?
| | Fentanyl | 2 | 2011 | 115 | 0.150 |
Why?
| | Vascular Diseases | 2 | 2019 | 240 | 0.150 |
Why?
| | Bilirubin | 3 | 1995 | 89 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 21 | 0.150 |
Why?
| | Taurine | 1 | 2019 | 40 | 0.150 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 64 | 0.150 |
Why?
| | Imidazoles | 1 | 2000 | 239 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 101 | 0.150 |
Why?
| | Caspase 3 | 2 | 2017 | 251 | 0.150 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 183 | 0.140 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 25 | 0.140 |
Why?
| | Legislation, Drug | 1 | 1999 | 83 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Homocystinuria | 1 | 2019 | 62 | 0.140 |
Why?
| | Systems Biology | 1 | 2019 | 69 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 219 | 0.140 |
Why?
| | Naphthalenes | 1 | 1998 | 58 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 329 | 0.140 |
Why?
| | Creatinine | 5 | 2022 | 485 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 422 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 45 | 0.140 |
Why?
| | Iohexol | 1 | 2018 | 22 | 0.140 |
Why?
| | Reference Values | 4 | 2013 | 801 | 0.140 |
Why?
| | Vascular Access Devices | 1 | 2018 | 26 | 0.140 |
Why?
| | Excipients | 1 | 2018 | 55 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 36 | 0.140 |
Why?
| | Genotype | 5 | 2019 | 1849 | 0.140 |
Why?
| | Phospholipids | 5 | 2013 | 219 | 0.140 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 27 | 0.140 |
Why?
| | Enzyme Activation | 2 | 2017 | 819 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 21 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2025 | 834 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Glucuronides | 2 | 2022 | 19 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Sex Factors | 3 | 2019 | 2050 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 9 | 0.130 |
Why?
| | Cells, Cultured | 10 | 2017 | 4182 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 63 | 0.130 |
Why?
| | Acute Kidney Injury | 2 | 2018 | 812 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 907 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.130 |
Why?
| | Enzyme Stability | 1 | 2017 | 72 | 0.130 |
Why?
| | Guanosine | 1 | 2017 | 41 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 126 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2017 | 191 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 286 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 150 | 0.130 |
Why?
| | Glutathione | 4 | 2009 | 357 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 173 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.130 |
Why?
| | Plasma | 2 | 2017 | 220 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 287 | 0.130 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 217 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 70 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2021 | 538 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Ischemia | 2 | 2012 | 414 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1165 | 0.120 |
Why?
| | Necrosis | 1 | 2017 | 248 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2016 | 649 | 0.120 |
Why?
| | Vitamin D | 1 | 2019 | 399 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 314 | 0.120 |
Why?
| | Laboratory Proficiency Testing | 1 | 2015 | 8 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 1996 | 292 | 0.120 |
Why?
| | Gastrectomy | 1 | 2017 | 132 | 0.120 |
Why?
| | Tunica Intima | 2 | 2010 | 76 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2007 | 147 | 0.120 |
Why?
| | Mutation | 2 | 2022 | 3984 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 260 | 0.120 |
Why?
| | Hepatocytes | 2 | 2006 | 211 | 0.120 |
Why?
| | Propofol | 1 | 2016 | 88 | 0.120 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 80 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 209 | 0.120 |
Why?
| | Sex Characteristics | 3 | 2023 | 766 | 0.120 |
Why?
| | Cerebral Cortex | 2 | 2024 | 452 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 288 | 0.110 |
Why?
| | Sulfonamides | 2 | 2025 | 505 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 181 | 0.110 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.110 |
Why?
| | Cholestasis | 3 | 1995 | 208 | 0.110 |
Why?
| | Larva | 1 | 2016 | 234 | 0.110 |
Why?
| | HIV Infections | 3 | 2019 | 2945 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 110 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 358 | 0.110 |
Why?
| | Extinction, Psychological | 1 | 2015 | 88 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1085 | 0.110 |
Why?
| | Benzamides | 3 | 2009 | 213 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 216 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 434 | 0.110 |
Why?
| | Pharmacokinetics | 3 | 2020 | 31 | 0.110 |
Why?
| | C-Reactive Protein | 3 | 2022 | 411 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | Rabbits | 3 | 2017 | 762 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1742 | 0.110 |
Why?
| | Specimen Handling | 1 | 2015 | 182 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 636 | 0.110 |
Why?
| | Carbon Isotopes | 2 | 2024 | 140 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | United States | 5 | 2020 | 15074 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 102 | 0.110 |
Why?
| | Prognosis | 4 | 2018 | 3995 | 0.110 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2006 | 198 | 0.100 |
Why?
| | Altitude Sickness | 2 | 2006 | 148 | 0.100 |
Why?
| | Mental Recall | 1 | 2015 | 207 | 0.100 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 35 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 24 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 272 | 0.100 |
Why?
| | Apoptosis | 4 | 2017 | 2551 | 0.100 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 45 | 0.100 |
Why?
| | Drug Resistance, Multiple | 3 | 2002 | 25 | 0.100 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 59 | 0.100 |
Why?
| | Fatty Acids | 2 | 2014 | 445 | 0.100 |
Why?
| | Brachial Artery | 3 | 2019 | 202 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 108 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Adenosine Triphosphate | 4 | 2004 | 490 | 0.100 |
Why?
| | Schizophrenia | 1 | 2017 | 451 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 56 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1237 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 7 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 57 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1857 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 73 | 0.100 |
Why?
| | Calibration | 4 | 2019 | 149 | 0.100 |
Why?
| | Iron | 2 | 2010 | 324 | 0.100 |
Why?
| | Graft vs Host Disease | 2 | 2000 | 252 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 78 | 0.090 |
Why?
| | Oncogene Proteins | 1 | 2012 | 58 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 790 | 0.090 |
Why?
| | Models, Theoretical | 3 | 2025 | 581 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 20 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 105 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 131 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 576 | 0.090 |
Why?
| | Monitoring, Physiologic | 3 | 2012 | 280 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2020 | 15901 | 0.090 |
Why?
| | Swine, Miniature | 2 | 2010 | 90 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 621 | 0.090 |
Why?
| | Down Syndrome | 1 | 2018 | 483 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 224 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Association Learning | 1 | 2012 | 63 | 0.090 |
Why?
| | Vagus Nerve | 1 | 2012 | 88 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 280 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 65 | 0.090 |
Why?
| | Hot Flashes | 1 | 2012 | 87 | 0.090 |
Why?
| | Ritonavir | 1 | 2011 | 75 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 163 | 0.090 |
Why?
| | Morphine Derivatives | 1 | 2011 | 19 | 0.090 |
Why?
| | Lung | 9 | 2013 | 4103 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 560 | 0.090 |
Why?
| | Disease Progression | 4 | 2022 | 2752 | 0.090 |
Why?
| | Consumer Product Safety | 1 | 2011 | 33 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Cell Cycle | 2 | 2011 | 593 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2013 | 335 | 0.090 |
Why?
| | Internet | 1 | 2015 | 674 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 855 | 0.090 |
Why?
| | Survival Analysis | 2 | 2012 | 1311 | 0.090 |
Why?
| | Methylation | 1 | 2011 | 227 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 278 | 0.080 |
Why?
| | Tachyphylaxis | 1 | 2010 | 5 | 0.080 |
Why?
| | Cholinergic Agents | 1 | 2010 | 18 | 0.080 |
Why?
| | Structure-Activity Relationship | 5 | 2013 | 570 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 769 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3143 | 0.080 |
Why?
| | Verapamil | 2 | 2009 | 40 | 0.080 |
Why?
| | Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 2 | 2017 | 39 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 23 | 0.080 |
Why?
| | Sensation | 1 | 2010 | 56 | 0.080 |
Why?
| | Needs Assessment | 1 | 2012 | 381 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 162 | 0.080 |
Why?
| | Tablets, Enteric-Coated | 2 | 2007 | 5 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 65 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 299 | 0.080 |
Why?
| | Micromonosporaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 496 | 0.080 |
Why?
| | Albuminuria | 1 | 2010 | 185 | 0.080 |
Why?
| | Conditioning, Classical | 2 | 2024 | 107 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 96 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2014 | 670 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 189 | 0.080 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.080 |
Why?
| | Diclofenac | 1 | 2009 | 15 | 0.080 |
Why?
| | Neoplasms | 2 | 2016 | 2687 | 0.080 |
Why?
| | Risk Factors | 5 | 2025 | 10385 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 464 | 0.080 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 334 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 375 | 0.080 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 23 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2021 | 156 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 12 | 0.080 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2012 | 193 | 0.080 |
Why?
| | Loperamide | 1 | 2009 | 12 | 0.080 |
Why?
| | Radioimmunoassay | 6 | 1996 | 169 | 0.070 |
Why?
| | Surface Properties | 3 | 2019 | 411 | 0.070 |
Why?
| | Cross Reactions | 2 | 2007 | 130 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 118 | 0.070 |
Why?
| | Aorta | 2 | 2003 | 416 | 0.070 |
Why?
| | Creatine | 2 | 2006 | 60 | 0.070 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 345 | 0.070 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2006 | 65 | 0.070 |
Why?
| | Species Specificity | 2 | 2008 | 581 | 0.070 |
Why?
| | Drug Evaluation | 2 | 2000 | 84 | 0.070 |
Why?
| | Kidney Medulla | 1 | 2008 | 31 | 0.070 |
Why?
| | Lymphocyte Activation | 6 | 2003 | 1148 | 0.070 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 27 | 0.070 |
Why?
| | Automation | 2 | 2016 | 98 | 0.070 |
Why?
| | Guinea Pigs | 1 | 2008 | 170 | 0.070 |
Why?
| | Taste | 2 | 2024 | 230 | 0.070 |
Why?
| | Hydroxybutyrates | 2 | 2005 | 14 | 0.070 |
Why?
| | Cytokines | 4 | 2025 | 2083 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2025 | 980 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 259 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 142 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Rats, Inbred F344 | 1 | 2008 | 267 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1076 | 0.070 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 178 | 0.070 |
Why?
| | Enzymes | 1 | 2008 | 64 | 0.070 |
Why?
| | Macaca mulatta | 1 | 2008 | 186 | 0.070 |
Why?
| | Drug Combinations | 3 | 2024 | 346 | 0.070 |
Why?
| | Switzerland | 1 | 2007 | 39 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 344 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 397 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2011 | 122 | 0.070 |
Why?
| | Emulsions | 5 | 2016 | 55 | 0.070 |
Why?
| | Nanoparticles | 1 | 2013 | 469 | 0.070 |
Why?
| | Myocardial Infarction | 2 | 2007 | 1063 | 0.070 |
Why?
| | Acute Disease | 6 | 2005 | 993 | 0.070 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.070 |
Why?
| | Prosthesis Design | 2 | 2025 | 333 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2138 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2013 | 121 | 0.070 |
Why?
| | NAD | 2 | 2004 | 79 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 285 | 0.070 |
Why?
| | Serum Albumin | 3 | 2019 | 151 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 68 | 0.070 |
Why?
| | Cardiotonic Agents | 1 | 2007 | 95 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 186 | 0.060 |
Why?
| | Caco-2 Cells | 3 | 2003 | 78 | 0.060 |
Why?
| | Immune Tolerance | 3 | 2017 | 366 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5152 | 0.060 |
Why?
| | Liver Diseases | 2 | 2024 | 290 | 0.060 |
Why?
| | Nitric Oxide | 3 | 2017 | 892 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1103 | 0.060 |
Why?
| | Fetus | 2 | 2021 | 800 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 45 | 0.060 |
Why?
| | Lactic Acid | 4 | 2009 | 303 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 409 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 571 | 0.060 |
Why?
| | Food-Drug Interactions | 1 | 2005 | 11 | 0.060 |
Why?
| | Macaca | 1 | 2006 | 64 | 0.060 |
Why?
| | Body Weight | 5 | 2001 | 996 | 0.060 |
Why?
| | Growth Inhibitors | 1 | 2005 | 45 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2005 | 30 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2086 | 0.060 |
Why?
| | Lactates | 1 | 2005 | 85 | 0.060 |
Why?
| | Methylamines | 1 | 2005 | 34 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 377 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 107 | 0.060 |
Why?
| | Ships | 1 | 1985 | 6 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
| | Phosphorylation | 5 | 2012 | 1767 | 0.060 |
Why?
| | Posture | 1 | 2006 | 192 | 0.060 |
Why?
| | Organ Size | 3 | 2015 | 471 | 0.060 |
Why?
| | Iliac Artery | 2 | 2017 | 57 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 98 | 0.060 |
Why?
| | Streptozocin | 1 | 2005 | 23 | 0.060 |
Why?
| | Hair | 1 | 2025 | 88 | 0.060 |
Why?
| | Triglycerides | 3 | 2011 | 513 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 638 | 0.060 |
Why?
| | CD55 Antigens | 1 | 2005 | 29 | 0.060 |
Why?
| | Hot Temperature | 2 | 2012 | 392 | 0.060 |
Why?
| | Paraplegia | 1 | 1985 | 61 | 0.060 |
Why?
| | Colorado | 5 | 2021 | 4543 | 0.060 |
Why?
| | Complement Inactivator Proteins | 1 | 2005 | 42 | 0.060 |
Why?
| | Warfarin | 1 | 2006 | 153 | 0.060 |
Why?
| | Drug Design | 1 | 2005 | 165 | 0.060 |
Why?
| | Troleandomycin | 3 | 1999 | 3 | 0.060 |
Why?
| | Hippocampus | 1 | 2010 | 929 | 0.060 |
Why?
| | Steroids | 2 | 2005 | 163 | 0.050 |
Why?
| | Saccharin | 1 | 2024 | 6 | 0.050 |
Why?
| | Vasodilation | 2 | 2018 | 509 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 72 | 0.050 |
Why?
| | Insulin Infusion Systems | 1 | 2009 | 447 | 0.050 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1109 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2005 | 122 | 0.050 |
Why?
| | Consensus | 2 | 2019 | 683 | 0.050 |
Why?
| | Calcineurin | 2 | 2004 | 107 | 0.050 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 196 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 27 | 0.050 |
Why?
| | Stress, Psychological | 2 | 2025 | 1124 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 801 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1893 | 0.050 |
Why?
| | Trimethylsilyl Compounds | 1 | 2004 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 36 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 1068 | 0.050 |
Why?
| | Saliva | 1 | 2025 | 240 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2005 | 203 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2994 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1441 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 91 | 0.050 |
Why?
| | Analysis of Variance | 2 | 1997 | 1317 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 234 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 138 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2004 | 194 | 0.050 |
Why?
| | Midazolam | 1 | 2003 | 69 | 0.050 |
Why?
| | Protein Binding | 3 | 2018 | 2233 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 317 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 201 | 0.050 |
Why?
| | Insulin | 3 | 2009 | 2447 | 0.050 |
Why?
| | Pancreas Transplantation | 1 | 2003 | 66 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 2 | 2018 | 38 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 956 | 0.050 |
Why?
| | NADP | 2 | 1994 | 53 | 0.050 |
Why?
| | Altitude | 3 | 2017 | 467 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2009 | 898 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5884 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 427 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 162 | 0.050 |
Why?
| | Leukocytes | 1 | 2024 | 308 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2000 | 104 | 0.050 |
Why?
| | Ketoconazole | 2 | 1999 | 3 | 0.050 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 342 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2024 | 164 | 0.050 |
Why?
| | Sports | 1 | 1985 | 217 | 0.050 |
Why?
| | Cognition | 2 | 2023 | 1179 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2024 | 177 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 40 | 0.050 |
Why?
| | Oral Mucosal Absorption | 1 | 2021 | 1 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 1 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 44 | 0.050 |
Why?
| | Administration, Sublingual | 1 | 2021 | 12 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 550 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5530 | 0.050 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 22 | 0.050 |
Why?
| | Wine | 1 | 2001 | 12 | 0.050 |
Why?
| | Plant Preparations | 1 | 2002 | 38 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.050 |
Why?
| | Drug Overdose | 1 | 2006 | 346 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 58 | 0.040 |
Why?
| | Biological Transport | 2 | 2003 | 403 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 309 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2002 | 72 | 0.040 |
Why?
| | Cell Survival | 3 | 2012 | 1126 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 120 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 80 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 115 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2024 | 512 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 842 | 0.040 |
Why?
| | Glomerular Mesangium | 2 | 1991 | 21 | 0.040 |
Why?
| | Microchemistry | 3 | 2000 | 19 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.040 |
Why?
| | Haplotypes | 2 | 2013 | 497 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.040 |
Why?
| | Gene Silencing | 2 | 2012 | 196 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 434 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 501 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2030 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1730 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2013 | 361 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 241 | 0.040 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 46 | 0.040 |
Why?
| | Pyrazoles | 1 | 2004 | 425 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
| | LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
| | Antimetabolites | 1 | 2000 | 21 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 142 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 275 | 0.040 |
Why?
| | Reward | 1 | 2022 | 251 | 0.040 |
Why?
| | Logistic Models | 2 | 2022 | 2093 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 471 | 0.040 |
Why?
| | Risk Assessment | 3 | 2018 | 3466 | 0.040 |
Why?
| | Heart | 1 | 2003 | 612 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 408 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1999 | 18 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2241 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.040 |
Why?
| | Rats, Inbred BN | 4 | 2000 | 56 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 194 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.040 |
Why?
| | Attention | 1 | 2023 | 443 | 0.040 |
Why?
| | Citrus | 1 | 1999 | 8 | 0.040 |
Why?
| | K562 Cells | 2 | 2009 | 91 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 171 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 2001 | 1437 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1285 | 0.040 |
Why?
| | Epithelium | 1 | 2000 | 316 | 0.040 |
Why?
| | Maternal Age | 1 | 2019 | 127 | 0.040 |
Why?
| | Beverages | 1 | 1999 | 68 | 0.040 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 206 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Individuality | 1 | 2000 | 158 | 0.040 |
Why?
| | Antigens, CD | 1 | 2001 | 537 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1249 | 0.040 |
Why?
| | Amides | 1 | 1999 | 97 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 169 | 0.040 |
Why?
| | Ultrafiltration | 1 | 2018 | 30 | 0.040 |
Why?
| | Europe | 1 | 1999 | 407 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 35 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 225 | 0.040 |
Why?
| | Sus scrofa | 1 | 2018 | 58 | 0.040 |
Why?
| | F2-Isoprostanes | 2 | 2009 | 21 | 0.040 |
Why?
| | Ions | 1 | 2018 | 67 | 0.030 |
Why?
| | Nitriles | 1 | 1999 | 176 | 0.030 |
Why?
| | Solutions | 2 | 2016 | 168 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1192 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2018 | 66 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Nifedipine | 1 | 1997 | 28 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 413 | 0.030 |
Why?
| | Urea | 1 | 2018 | 79 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 1998 | 124 | 0.030 |
Why?
| | Bioreactors | 1 | 2018 | 48 | 0.030 |
Why?
| | Bronchi | 1 | 1999 | 269 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1998 | 103 | 0.030 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 433 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 538 | 0.030 |
Why?
| | Food Hypersensitivity | 2 | 2011 | 182 | 0.030 |
Why?
| | Intestines | 1 | 2000 | 356 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2011 | 202 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 187 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2017 | 72 | 0.030 |
Why?
| | Archaeal Proteins | 1 | 2017 | 45 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2159 | 0.030 |
Why?
| | Postoperative Care | 1 | 1999 | 273 | 0.030 |
Why?
| | Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1070 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1140 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 365 | 0.030 |
Why?
| | Schizophrenic Psychology | 1 | 2017 | 98 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2008 | 157 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Temperature | 1 | 2000 | 660 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 376 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2017 | 60 | 0.030 |
Why?
| | Hydrolysis | 2 | 2013 | 194 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2925 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 30 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 193 | 0.030 |
Why?
| | Catheterization | 1 | 2017 | 182 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 64 | 0.030 |
Why?
| | Cell Count | 2 | 2013 | 325 | 0.030 |
Why?
| | Anterior Chamber | 1 | 1996 | 26 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 668 | 0.030 |
Why?
| | Materials Testing | 1 | 2018 | 350 | 0.030 |
Why?
| | Anesthesia, Intravenous | 1 | 2016 | 24 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2010 | 2516 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 353 | 0.030 |
Why?
| | Nonlinear Dynamics | 1 | 2016 | 88 | 0.030 |
Why?
| | Bromocriptine | 1 | 1996 | 31 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 1996 | 53 | 0.030 |
Why?
| | Duodenum | 1 | 1996 | 74 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2390 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 372 | 0.030 |
Why?
| | Nicotinic Agonists | 1 | 2017 | 134 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 580 | 0.030 |
Why?
| | Syringes | 1 | 2016 | 43 | 0.030 |
Why?
| | Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 475 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2007 | 1924 | 0.030 |
Why?
| | Health Policy | 1 | 1999 | 398 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 675 | 0.030 |
Why?
| | Incidence | 2 | 2018 | 2830 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 684 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 44 | 0.030 |
Why?
| | Neuroglia | 1 | 1996 | 173 | 0.030 |
Why?
| | Estradiol | 1 | 2019 | 525 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 411 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 319 | 0.030 |
Why?
| | Citric Acid Cycle | 2 | 2010 | 59 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
| | Safety | 1 | 2017 | 348 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 421 | 0.030 |
Why?
| | Rhodamines | 1 | 1995 | 20 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1995 | 37 | 0.030 |
Why?
| | Heat-Shock Proteins | 2 | 2007 | 142 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 1996 | 539 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 24 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 19 | 0.030 |
Why?
| | Oxides | 1 | 1995 | 47 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 254 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 383 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 1996 | 359 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 413 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 391 | 0.030 |
Why?
| | Pain Measurement | 2 | 2010 | 549 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1995 | 55 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 595 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 89 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Kidney Function Tests | 3 | 2006 | 156 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 56 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 95 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 920 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 451 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 3 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 127 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 13 | 0.030 |
Why?
| | Nevirapine | 1 | 2013 | 18 | 0.030 |
Why?
| | Benzoxazines | 1 | 2013 | 31 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2013 | 69 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 1999 | 86 | 0.030 |
Why?
| | Phospholipases | 1 | 2013 | 14 | 0.030 |
Why?
| | Cognition Disorders | 1 | 2017 | 511 | 0.030 |
Why?
| | Mannitol | 2 | 2006 | 38 | 0.030 |
Why?
| | Alkynes | 1 | 2013 | 61 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2013 | 25 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2362 | 0.030 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 486 | 0.020 |
Why?
| | Models, Molecular | 2 | 2013 | 1597 | 0.020 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 56 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 48 | 0.020 |
Why?
| | Heart Rate | 2 | 2009 | 801 | 0.020 |
Why?
| | Laparoscopy | 1 | 2017 | 452 | 0.020 |
Why?
| | Mothers | 1 | 2019 | 765 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 695 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 394 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 201 | 0.020 |
Why?
| | Leucovorin | 1 | 2012 | 85 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 98 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 74 | 0.020 |
Why?
| | Vascular System Injuries | 1 | 2013 | 76 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3705 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Asialoglycoprotein Receptor | 2 | 2006 | 6 | 0.020 |
Why?
| | Fear | 1 | 2015 | 344 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 153 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 204 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 29 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 29 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2007 | 745 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1610 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 193 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1093 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 32 | 0.020 |
Why?
| | Phenobarbital | 1 | 1991 | 18 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 1991 | 22 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 787 | 0.020 |
Why?
| | Actins | 2 | 2007 | 419 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 176 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 175 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 19 | 0.020 |
Why?
| | Femoral Artery | 1 | 2013 | 182 | 0.020 |
Why?
| | Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 195 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 573 | 0.020 |
Why?
| | Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 76 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 281 | 0.020 |
Why?
| | Contrast Media | 1 | 1995 | 463 | 0.020 |
Why?
| | Fluorouracil | 1 | 2012 | 204 | 0.020 |
Why?
| | Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 7 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 1991 | 29 | 0.020 |
Why?
| | Centrifugation | 1 | 1991 | 27 | 0.020 |
Why?
| | Immunoenzyme Techniques | 3 | 1996 | 209 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 569 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 194 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 373 | 0.020 |
Why?
| | Food Analysis | 1 | 2011 | 26 | 0.020 |
Why?
| | Alfentanil | 1 | 2010 | 7 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2591 | 0.020 |
Why?
| | Aldehydes | 1 | 1991 | 143 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 111 | 0.020 |
Why?
| | Pain Perception | 1 | 2010 | 24 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1058 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 626 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2849 | 0.020 |
Why?
| | Cell Division | 3 | 2001 | 794 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 199 | 0.020 |
Why?
| | Serologic Tests | 1 | 2010 | 54 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 888 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 890 | 0.020 |
Why?
| | Protein Conformation | 1 | 2013 | 944 | 0.020 |
Why?
| | Blood | 2 | 2000 | 113 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 157 | 0.020 |
Why?
| | Spinacia oleracea | 1 | 2009 | 9 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 97 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1009 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2010 | 141 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 88 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 192 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 366 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Serbia | 1 | 2008 | 7 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2009 | 50 | 0.020 |
Why?
| | Insulin Lispro | 1 | 2009 | 41 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2009 | 91 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 624 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 114 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 368 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 196 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 225 | 0.020 |
Why?
| | Urinalysis | 1 | 2009 | 77 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5744 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2008 | 34 | 0.020 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 41 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 326 | 0.020 |
Why?
| | Naloxone | 1 | 2009 | 123 | 0.020 |
Why?
| | Monocrotaline | 1 | 2007 | 35 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 14 | 0.020 |
Why?
| | HIV-1 | 1 | 2013 | 886 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1985 | 0.020 |
Why?
| | Fasting | 1 | 2009 | 283 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 345 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 852 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2007 | 48 | 0.020 |
Why?
| | Systole | 1 | 2007 | 174 | 0.020 |
Why?
| | Technetium | 1 | 2006 | 9 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 5 | 0.020 |
Why?
| | Radiography | 2 | 2000 | 839 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 2006 | 13 | 0.020 |
Why?
| | Cell Size | 2 | 1997 | 89 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1988 | 299 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 290 | 0.020 |
Why?
| | Dosage Forms | 2 | 1996 | 9 | 0.020 |
Why?
| | Serum Albumin, Human | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2006 | 39 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 23 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 10 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2006 | 116 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1261 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 42 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 62 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 151 | 0.020 |
Why?
| | Insulin, Regular, Human | 1 | 2006 | 48 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 126 | 0.020 |
Why?
| | Portal System | 1 | 2006 | 12 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 824 | 0.020 |
Why?
| | Insulin, Long-Acting | 1 | 2006 | 63 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 362 | 0.020 |
Why?
| | Cold Ischemia | 1 | 2006 | 32 | 0.020 |
Why?
| | Biopsy | 2 | 2000 | 1072 | 0.020 |
Why?
| | Electroencephalography | 1 | 2009 | 444 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 984 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 86 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2006 | 241 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2007 | 303 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2850 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2009 | 357 | 0.010 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2006 | 85 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 201 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 101 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2006 | 335 | 0.010 |
Why?
| | Escherichia coli | 1 | 2009 | 827 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1996 | 441 | 0.010 |
Why?
| | Travel | 1 | 2006 | 134 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 109 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 524 | 0.010 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1487 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 351 | 0.010 |
Why?
| | Motor Skills | 1 | 1985 | 100 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1047 | 0.010 |
Why?
| | Polymers | 1 | 2008 | 488 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2171 | 0.010 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 548 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 241 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2006 | 262 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 584 | 0.010 |
Why?
| | Absorption | 1 | 2003 | 60 | 0.010 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2745 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 502 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 2003 | 82 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 93 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 177 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2003 | 136 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 152 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1084 | 0.010 |
Why?
| | gamma-Glutamyltransferase | 2 | 1994 | 42 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 33 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 175 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1995 | 3636 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 197 | 0.010 |
Why?
| | Alkaline Phosphatase | 2 | 1994 | 149 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 8 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 150 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2001 | 28 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 377 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 31 | 0.010 |
Why?
| | Transfection | 1 | 2003 | 942 | 0.010 |
Why?
| | Calorimetry | 1 | 2001 | 71 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1804 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2001 | 148 | 0.010 |
Why?
| | Cell Membrane | 2 | 1995 | 716 | 0.010 |
Why?
| | Quantum Theory | 1 | 2001 | 92 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 246 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1737 | 0.010 |
Why?
| | Coloring Agents | 1 | 2000 | 95 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 66 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 97 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 350 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 990 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1991 | 51 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2006 | 792 | 0.010 |
Why?
| | Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2815 | 0.010 |
Why?
| | Crotonates | 1 | 1999 | 5 | 0.010 |
Why?
| | Toluidines | 1 | 1999 | 7 | 0.010 |
Why?
| | Remission Induction | 1 | 2000 | 292 | 0.010 |
Why?
| | Vinblastine | 1 | 1999 | 71 | 0.010 |
Why?
| | Capsules | 2 | 1990 | 39 | 0.010 |
Why?
| | Thermodynamics | 1 | 2001 | 423 | 0.010 |
Why?
| | Ultrasonography | 1 | 2003 | 748 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2004 | 707 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1999 | 110 | 0.010 |
Why?
| | Isoxazoles | 1 | 1999 | 53 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 355 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 433 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1999 | 104 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1999 | 522 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1999 | 172 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1317 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2000 | 450 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 663 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 229 | 0.010 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
| | Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
| | Tissue Donors | 1 | 2000 | 395 | 0.010 |
Why?
| | Azathioprine | 1 | 1996 | 49 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 995 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1473 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1996 | 91 | 0.010 |
Why?
| | Administration, Topical | 1 | 1996 | 149 | 0.010 |
Why?
| | Ophthalmic Solutions | 1 | 1996 | 78 | 0.010 |
Why?
| | Acetonitriles | 1 | 1995 | 12 | 0.010 |
Why?
| | Bile Canaliculi | 1 | 1995 | 4 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1701 | 0.010 |
Why?
| | Albumins | 1 | 1996 | 115 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1996 | 140 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 309 | 0.010 |
Why?
| | Fetuins | 1 | 1995 | 2 | 0.010 |
Why?
| | Cornea | 1 | 1996 | 150 | 0.010 |
Why?
| | Cataract Extraction | 1 | 1996 | 105 | 0.010 |
Why?
| | Ferrosoferric Oxide | 1 | 1995 | 24 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 37 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 1996 | 195 | 0.010 |
Why?
| | Skin | 1 | 1999 | 756 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 175 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1996 | 329 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1994 | 187 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1995 | 466 | 0.010 |
Why?
| | Vinca Alkaloids | 1 | 1993 | 6 | 0.010 |
Why?
| | Affinity Labels | 1 | 1993 | 24 | 0.010 |
Why?
| | Succinimides | 1 | 1993 | 19 | 0.010 |
Why?
| | Daunorubicin | 1 | 1993 | 24 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1730 | 0.010 |
Why?
| | Collagen | 1 | 1996 | 459 | 0.010 |
Why?
| | Bile Acids and Salts | 1 | 1994 | 151 | 0.010 |
Why?
| | Cricetulus | 1 | 1993 | 110 | 0.010 |
Why?
| | CHO Cells | 1 | 1993 | 167 | 0.010 |
Why?
| | Cricetinae | 1 | 1993 | 297 | 0.010 |
Why?
| | Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 149 | 0.010 |
Why?
| | Tritium | 1 | 1992 | 72 | 0.010 |
Why?
| | Water | 1 | 1995 | 461 | 0.010 |
Why?
| | Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
| | Cholinesterases | 1 | 1991 | 9 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 167 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1991 | 83 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1991 | 147 | 0.010 |
Why?
| | Oils | 1 | 1990 | 21 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1993 | 737 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1994 | 719 | 0.000 |
Why?
| | Antigen-Antibody Reactions | 1 | 1987 | 54 | 0.000 |
Why?
| | Gelatin | 1 | 1988 | 55 | 0.000 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 97 | 0.000 |
Why?
| | CD3 Complex | 1 | 1987 | 104 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1987 | 718 | 0.000 |
Why?
|
|
Christians's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|